SignalCorporate
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
ALNY fell 25% despite Q3 earnings beat due to demand growth concerns.
Context
What happened: Alnylam Pharmaceuticals $ALNY reported third-quarter 2026 adjusted earnings of $16.26 per share and revenue of $1.46 billion, both beating consensus, yet shares fell 25.1%.
Key numbers: Adjusted EPS $16.26 vs $2.19 consensus, aided by a roughly $1.9 billion noncash tax benefit. Revenue up 17% to $1.46 billion.
Why it matters: Investors focused on slower-than-expected Amvuttra patient demand and management's expectation that combined Amvuttra and Onpattro sales will finish 2026 near the low end of guidance, outweighing the headline earnings beat.
Market: -3.8% today ($169.36), -57.7% YTD, 0.7x vol — as of 15:32 UTC
Verified: Q3_2026 (Oct 29) EPS $16.26 vs $2.25 est, +623.0% beat; next print ~Jan 28
What changed
Alnylam Pharmaceuticals $ALNY reported third-quarter 2026 adjusted earnings of $16.26 per share and revenue of $1.46 billion, both beating consensus, yet shares fell 25.1%.
Why it matters
Investors focused on slower-than-expected Amvuttra patient demand and management's expectation that combined Amvuttra and Onpattro sales will finish 2026 near the low end of guidance, outweighing the headline earnings beat.
Market: -3.8% today ($169.36), -57.7% YTD, 0.7x vol — as of 15:32 UTC
Verified: Q3_2026 (Oct 29) EPS $16.26 vs $2.25 est, +623.0% beat; next print ~Jan 28